Download Files:
Chiauranib
$250 – $1,780
Products Details
Product Description
– Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects[1].
Web ID
– HY-124526
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C27H21N3O3
References
– [1]You Zhou, et al. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Cancer Sci. 2017 Mar;108(3):469-477.
CAS Number
– 1256349-48-0
Molecular Weight
– 435.47
Compound Purity
– 99.28
SMILES
– O=C(NC1=CC=CC=C1N)C2=C3C=CC(OC4=CC=NC5=CC(OC)=CC=C54)=CC3=CC=C2
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : 62.5 mg/mL (ultrasonic)
Target
– Aurora Kinase;c-Fms;c-Kit;PDGFR;VEGFR
Isoform
– Aurora B;PDGFRα;PDGFRβ;VEGFR1/Flt-1;VEGFR2/KDR/Flk-1;VEGFR3/Flt-4
Pathway
– Cell Cycle/DNA Damage;Epigenetics;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
